The importance of pharmacological synergy in psychoactive herbal medicines

Alternative Medicine Review

Volumn 7, Issue 2, 2002, Pages 130-137

  Spinella, Marcello ^a  

^a RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; HYPERFORIN; HYPERICIN; KAVA; LACTONE; PHLOROGLUCINOL; VALERIAN;

DRUG ABSORPTION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; EXTRACTION; FACILITATION; HERBAL MEDICINE; HYPERICUM PERFORATUM; REVIEW;

DRUG SYNERGISM; KAVA; PHYTOTHERAPY; PLANT COMPONENTS; PLANT PREPARATIONS; PSYCHOTROPIC DRUGS; VALERIAN;

EID: 0036241566     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Behavioral and molecular actions of caffeine: Focus on adenosine
2. Barbiturate-benzodiazepine interactions at the gamma-aminobutyric acidA receptor in rat cerebral cortical synaptoneurosomes
3. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state
4. Positive allosteric modulators of the GABA(A) receptor: Differential interaction of benzodiazepines and neuroactive steroids with ethanol
5. Mechanisms of depressant drug action/interaction
6. Hyperforin as a possible antidepressant component of hypericum extracts
7. Antidepressant activity of Hypericum perforatum and hyperforin: The neglected possibility
8. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity
9. St. John's wort for depression: A meta-analysis of well-defined clinical trials
10. St John's wort for depression-an overview and meta-analysis of randomised clinical trials
11. Biologically active and other chemical constituents of the herb of Hypericum perforatum L
12. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L
13. Inhibition of MAO by fractions and constituents of hypericum extract
14. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity
15. Inhibition of MAO and COMT by Hypericum extracts and hypericin
16. An antifungal gamma-pyrone and xanthones with monoamine oxidase inhibitory activity from Hypericum brasiliense
17. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract
18. St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy
19. Neuropharmacology of St. John's wort (Hypericum)
20. Clomipramine augmentation in treatment-resistant depression
21. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors
22. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis
23. D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness
24. Uptake into mouse brain of four compounds present in the psychoactive beverage kava
25. Influence of genuine kavapyrone enantiomers on the GABA-A binding site
26. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain
27. Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltagegated Na+ channels
28. The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, ATP content and intracellular Na+ and Ca2+ of anoxic brain vesicles
29. In vivo microdialysis study of (+/-)-kavain on veratridine-induced glutamate release
30. [3H]-monoamine uptake inhibition properties of kava pyrones
31. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)
32. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus
33. Different effects of L-type and T-type calcium channel blockers on the hypnotic potency of triazolam and zolpidem in rats
34. Positive interaction of ethanol and kava resin in mice
35. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance
36. The importance of new antidepressants in the treatment of anxiety/depressive disorders
37. Antidepressants for the treatment of generalized anxiety disorder. A placebocontrolled comparison of imipramine, trazodone, and diazepam
38. The biological activity of valerian and related plants
39. Effect of valeprotriate on spontaneous motor activity in mice
40. Evaluation of the activity on the mouse CNS of several plant extracts and a combination of them
41. Characterisation of the central nervous depressant activity of a commercially available valerian root extract
42. Biological activity of the sum of the valepotriates isolated from Valeriana alliariifolia
43. Studies on the effect of Harmonicum Much on sleep using polygraphic EEG recordings
44. The effect of valerian extract on sleep polygraphy in poor sleepers: A pilot study
45. Double blind study of a valerian preparation
46. Aqueous extract of valerian reduces latency to fall asleep in man
47. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man
48. An aqueous extract of valerian influences the transport of GABA in synaptosomes
49. Synaptosomal GABA release as influenced by valerian root extract-involvement of the GABA carrier
50. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes
51. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release
52. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives